MAFLD predicts cardiovascular disease risk better than MASLD
Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic ca...
Saved in:
Published in | Liver international Vol. 44; no. 7; pp. 1567 - 1574 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.07.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 1478-3223 1478-3231 1478-3231 |
DOI | 10.1111/liv.15931 |
Cover
Abstract | Background and Aim
Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).
Methods
Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed.
Results
MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone.
Conclusions
Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use. |
---|---|
AbstractList | Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).
Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed.
MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone.
Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use. Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).BACKGROUND AND AIMMetabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed.METHODSSix thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed.MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone.RESULTSMAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone.Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.CONCLUSIONSAlthough both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use. Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD). Methods Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed. Results MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone. Conclusions Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use. Background and AimMetabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).MethodsSix thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed.ResultsMAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone.ConclusionsAlthough both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use. |
Author | Méndez‐Sánchez, Nahum Eslam, Mohammed Pan, Ziyan Esmat, Gamal Shiha, Gamal |
Author_xml | – sequence: 1 givenname: Ziyan surname: Pan fullname: Pan, Ziyan organization: Westmead Hospital and University of Sydney – sequence: 2 givenname: Gamal orcidid: 0000-0002-9338-8854 surname: Shiha fullname: Shiha, Gamal organization: Mansoura University – sequence: 3 givenname: Gamal surname: Esmat fullname: Esmat, Gamal organization: Cairo University – sequence: 4 givenname: Nahum orcidid: 0000-0001-5257-8048 surname: Méndez‐Sánchez fullname: Méndez‐Sánchez, Nahum organization: Medica Sur Clinic Foundation – sequence: 5 givenname: Mohammed orcidid: 0000-0002-4315-4144 surname: Eslam fullname: Eslam, Mohammed email: mohammed.eslam@sydney.edu.au organization: Westmead Hospital and University of Sydney |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38641962$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kF1PwjAUhhuDkQ-98A-YJd7oxaBn3bot8YaAKMmIF37cNqXtYnFs2G4Y_r1FwAui5-acNM_7pnm6qFVWpULoEnAf3AwKve5DlBI4QR0I48QnAYHW7x2QNupau8AY0jSCM9QmCQ0hpUEH3c2Gk2zsrYySWtTWE9xIXa25FU3BjSe1Vdwqz2j74c1VXSvj1e-89GbD52x8jk5zXlh1sd899Dq5fxk9-tnTw3Q0zHxBIgK-wnSOAxA4oXGeU5njPKQR4ISDdFtCHKcRCbkKiaBA0zSGQCaxJHOcB8K99tDNrndlqs9G2ZottRWqKHipqsYygkOCYxqmW_T6CF1UjSnd7xxFE-cIU-qoqz3VzJdKspXRS2427ODFAYMdIExlrVE5E7rmta7K2nBdMMBsa5458-zHvEvcHiUOpX-x-_YvXajN_yDLpm-7xDczhI6T |
CitedBy_id | crossref_primary_10_1016_j_numecd_2025_104024 crossref_primary_10_1016_j_aohep_2024_101512 crossref_primary_10_1111_liv_70059 crossref_primary_10_1111_liv_15950 crossref_primary_10_1111_liv_15972 crossref_primary_10_20517_mtod_2024_39 crossref_primary_10_1111_liv_16099 crossref_primary_10_1111_liv_16096 crossref_primary_10_1007_s12072_024_10721_2 crossref_primary_10_1186_s12933_024_02434_5 crossref_primary_10_1016_j_aohep_2024_101573 crossref_primary_10_1186_s12876_025_03625_4 crossref_primary_10_1111_apt_18052 crossref_primary_10_1111_dom_16196 crossref_primary_10_1016_j_aohep_2024_101527 crossref_primary_10_1016_j_aohep_2024_101526 crossref_primary_10_1016_j_jhep_2024_08_005 crossref_primary_10_20517_mtod_2024_64 crossref_primary_10_20517_mtod_2024_143 crossref_primary_10_1111_liv_16000 crossref_primary_10_3389_fendo_2024_1494560 crossref_primary_10_1111_liv_16082 crossref_primary_10_1016_j_aohep_2024_101521 crossref_primary_10_1016_j_jhep_2024_12_019 crossref_primary_10_1007_s12072_024_10731_0 |
Cites_doi | 10.1186/s12933-022-01697-0 10.1210/clinem/dgac321 10.3390/ijms222111629 10.1007/s12072-023-10543-8 10.1016/j.cgh.2020.04.083 10.1016/j.jhep.2020.03.039 10.1111/hepr.13685 10.1007/s12072-020-10094-2 10.1093/gastro/got007 10.1161/01.cir.0000437741.48606.98 10.1007/s12072-023-10620-y 10.1016/j.cgh.2020.12.022 10.1161/CIRCULATIONAHA.116.022367 10.1016/S2468-1253(21)00132-1 10.1038/s41575-022-00635-5 10.1016/S2468-1253(21)00183-7 10.1053/j.gastro.2019.11.312 10.1016/j.cgh.2018.04.043 10.1007/s10620-022-07508-6 |
ContentType | Journal Article |
Copyright | 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2024 John Wiley & Sons A/S |
Copyright_xml | – notice: 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2024 John Wiley & Sons A/S |
DBID | AAYXX CITATION NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
DOI | 10.1111/liv.15931 |
DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1478-3231 |
EndPage | 1574 |
ExternalDocumentID | 38641962 10_1111_liv_15931 LIV15931 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: National Health and Medical Research Council of Australia (NHMRC) Program Grant funderid: APP1053206 – fundername: Project and ideas grants funderid: APP2001692; APP1107178; APP1108422 – fundername: National Health and Medical Research Council of Australia (NHMRC) Program Grant grantid: APP1053206 – fundername: Project and ideas grants grantid: APP1108422 – fundername: Project and ideas grants grantid: APP2001692 – fundername: Project and ideas grants grantid: APP1107178 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3531-e06b021c0867ff6df0f465108a1d651d1779534ae43c61699712d87d3b0f2ce43 |
IEDL.DBID | DR2 |
ISSN | 1478-3223 1478-3231 |
IngestDate | Tue Aug 05 11:13:14 EDT 2025 Wed Aug 13 07:20:46 EDT 2025 Thu Apr 03 07:04:56 EDT 2025 Tue Jul 01 04:10:11 EDT 2025 Thu Apr 24 22:59:01 EDT 2025 Wed Aug 20 07:26:49 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
License | 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3531-e06b021c0867ff6df0f465108a1d651d1779534ae43c61699712d87d3b0f2ce43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-9338-8854 0000-0001-5257-8048 0000-0002-4315-4144 |
PMID | 38641962 |
PQID | 3068931066 |
PQPubID | 2045125 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_3043076494 proquest_journals_3068931066 pubmed_primary_38641962 crossref_citationtrail_10_1111_liv_15931 crossref_primary_10_1111_liv_15931 wiley_primary_10_1111_liv_15931_LIV15931 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | July 2024 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Liver international |
PublicationTitleAlternate | Liver Int |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2014; 129 2023; 21 2021; 6 2013; 1 2021; 22 2023; 17 2020; 73 2021; 19 2023; 101133 2019; 17 2022; 67 2016; 134 2020; 14 2022; 21 2020; 158 2022; 107 2021; 51 2024; 18 2022; 19 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 Feng G (e_1_2_10_4_1) 2023; 21 Rinella ME (e_1_2_10_11_1) 2023; 101133 e_1_2_10_2_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 |
References_xml | – volume: 73 start-page: 202 issue: 1 year: 2020 end-page: 209 article-title: A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement publication-title: J Hepatol – volume: 6 start-page: 864 issue: 10 year: 2021 end-page: 873 article-title: Defining paediatric metabolic (dysfunction)‐associated fatty liver disease: an international expert consensus statement publication-title: Lancet Gastroenterol Hepatol – volume: 158 start-page: 1999 issue: 7 year: 2020 end-page: 2014.e1 article-title: MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease publication-title: Gastroenterology – volume: 134 start-page: 1430 issue: 19 year: 2016 end-page: 1440 article-title: Predicting the 10‐year risks of atherosclerotic cardiovascular disease in Chinese population: the China‐PAR project (prediction for ASCVD risk in China) publication-title: Circulation – volume: 19 start-page: 2138 issue: 10 year: 2021 end-page: 2147.e10 article-title: Metabolic dysfunction‐associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study publication-title: Clin Gastroenterol Hepatol – volume: 18 start-page: 168 issue: 1 year: 2024 end-page: 178 article-title: Breaking new ground: MASLD vs. MAFLD‐which holds the key for risk stratification? publication-title: Hepatol Int – volume: 17 start-page: 773 issue: 4 year: 2023 end-page: 791 article-title: An international multidisciplinary consensus statement on MAFLD and the risk of CVD publication-title: Hepatol Int – volume: 21 start-page: 1 year: 2023 end-page: 11 article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol – volume: 22 start-page: 11629 issue: 21 year: 2021 article-title: Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases publication-title: Int J Mol Sci – volume: 101133 start-page: E93 year: 2023 end-page: E94 article-title: A multi‐society Delphi consensus statement on new fatty liver disease nomenclature publication-title: Ann Hepatol – volume: 14 start-page: 889 issue: 6 year: 2020 end-page: 919 article-title: The Asian Pacific Association for the Study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease publication-title: Hepatol Int – volume: 21 start-page: 270 issue: 1 year: 2022 article-title: Metabolic dysfunction‐associated fatty liver disease and implications for cardiovascular risk and disease prevention publication-title: Cardiovasc Diabetol – volume: 67 start-page: 4919 issue: 10 year: 2022 end-page: 4928 article-title: MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check‐ups publication-title: Dig Dis Sci – volume: 6 start-page: 743 issue: 9 year: 2021 end-page: 753 article-title: Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases publication-title: Lancet Gastroenterol Hepatol – volume: 51 start-page: 1115 issue: 11 year: 2021 end-page: 1128 article-title: MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach publication-title: Hepatol Res – volume: 107 start-page: 2691 issue: 9 year: 2022 end-page: 2700 article-title: Global prevalence and clinical characteristics of metabolic‐associated fatty liver disease: a meta‐analysis and systematic review of 10 739 607 individuals publication-title: J Clin Endocrinol Metab – volume: 19 start-page: 638 issue: 10 year: 2022 end-page: 651 article-title: Metabolic (dysfunction)‐associated fatty liver disease in individuals of normal weight publication-title: Nat Rev Gastroenterol Hepatol – volume: 19 start-page: 136 issue: 1 year: 2021 end-page: 145.e6 article-title: Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic Steatohepatitis–related, child–Pugh a cirrhosis publication-title: Clin Gastroenterol Hepatol – volume: 129 start-page: S49 issue: 25_suppl_2 year: 2014 end-page: S73 article-title: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines publication-title: Circulation – volume: 17 start-page: 156 issue: 1 year: 2019 end-page: 163.e2 article-title: Vibration‐controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol – volume: 1 start-page: 19 issue: 1 year: 2013 end-page: 26 article-title: Update of liver fibrosis and steatosis with transient elastography (Fibroscan) publication-title: Gastroenterology Report – volume: 21 start-page: 1 year: 2023 ident: e_1_2_10_4_1 article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol – ident: e_1_2_10_7_1 doi: 10.1186/s12933-022-01697-0 – ident: e_1_2_10_2_1 doi: 10.1210/clinem/dgac321 – ident: e_1_2_10_6_1 doi: 10.3390/ijms222111629 – ident: e_1_2_10_18_1 doi: 10.1007/s12072-023-10543-8 – volume: 101133 start-page: E93 year: 2023 ident: e_1_2_10_11_1 article-title: A multi‐society Delphi consensus statement on new fatty liver disease nomenclature publication-title: Ann Hepatol – ident: e_1_2_10_5_1 doi: 10.1016/j.cgh.2020.04.083 – ident: e_1_2_10_8_1 doi: 10.1016/j.jhep.2020.03.039 – ident: e_1_2_10_19_1 doi: 10.1111/hepr.13685 – ident: e_1_2_10_16_1 doi: 10.1007/s12072-020-10094-2 – ident: e_1_2_10_15_1 doi: 10.1093/gastro/got007 – ident: e_1_2_10_12_1 doi: 10.1161/01.cir.0000437741.48606.98 – ident: e_1_2_10_22_1 doi: 10.1007/s12072-023-10620-y – ident: e_1_2_10_21_1 doi: 10.1016/j.cgh.2020.12.022 – ident: e_1_2_10_13_1 doi: 10.1161/CIRCULATIONAHA.116.022367 – ident: e_1_2_10_17_1 doi: 10.1016/S2468-1253(21)00132-1 – ident: e_1_2_10_3_1 doi: 10.1038/s41575-022-00635-5 – ident: e_1_2_10_10_1 doi: 10.1016/S2468-1253(21)00183-7 – ident: e_1_2_10_9_1 doi: 10.1053/j.gastro.2019.11.312 – ident: e_1_2_10_14_1 doi: 10.1016/j.cgh.2018.04.043 – ident: e_1_2_10_20_1 doi: 10.1007/s10620-022-07508-6 |
SSID | ssj0019951 |
Score | 2.574557 |
Snippet | Background and Aim
Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of... Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic... Background and AimMetabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1567 |
SubjectTerms | Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Fatty liver Health risks Liver Liver diseases Metabolism Risk Statistical analysis |
Title | MAFLD predicts cardiovascular disease risk better than MASLD |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.15931 https://www.ncbi.nlm.nih.gov/pubmed/38641962 https://www.proquest.com/docview/3068931066 https://www.proquest.com/docview/3043076494 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8QwFH6IB_HivoyOEkXES4e2ySQtehkcB5UZD254EEqTNiCOVWYR9Nf7ki44LiCeWtqELC8v733JWwD2qBZaxZ52ZOpKBCicObHm1EmDUMkAhayyWUt6F_z0hp3fNe-m4LD0hcnjQ1QHboYz7H5tGDyWw09M3n94baAstj7UHuUmbn77sgodZTyPLdhi5vofZWARVchY8VQ1J2XRNwVzUl-1AqczD_dlV3M7k8fGeCQb6v1LFMd_jmUB5gpFlLTylbMIU2m2BMutDEH40xvZJ9Y01J65L8FMr7iBX4ajXqvTbZOXgfkyGhI1Yc9KivseYizWibSuQsQczpNe66rbXoGbzsn18alTZGBwkETUc1KXS1QCFOIeoTVPtKtN7nQ3iL0En4knRNikLE4ZVdzjYSg8PwlEQqWrfYVfV2E6e87SdSBUxIjVONYUnLmxjzgmNGAGNToqkqaswUFJi0gV4clNlox-VMIUnKTITlINdquiL3lMjp8K1UuCRgVbDiPER6ifIQrmNdipfiNDmVuSOEufx6YMw32Ps5DVYC1fCFUrNOAMB-FjZy05f28-6p7d2peNvxfdhFkfVabcGLgO06PBON1ClWckt-3a_gAhiPf8 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD6qQBq8jI0C62DgTdPES6okdu1E4qUaVAWaPnBTX6YodmIJ0aVVL5PGr9-xc9HKQJp4SuLY8vX4fJ99fAzwlWqhVeJpR2auRILCmZNoTp0sCJUMUMkqe2tJNOT9W3Yx6owacFKdhSn8Q9QLbkYy7HxtBNwsSP8l5eP7X21UxuYQ9brdnzOQ6Kp2HmXOHlu6xYwBAGrB0q-QseOpk65qo38g5ipitSqntwU_qsIWliYP7eVCttXjEz-Or63NO3hbYlHSLQbPe2hk-TY0uzny8J-_yTdirUPtsvs2vInKTfgmnETd3uCUTGcmZDEnasWklZRbPsQYrRNpTwsRsz5Pou714HQHbntnN9_7TnkJg4O9RD0nc7lEHKCQ-giteapdba5Pd4PES_GZekKEHcqSjFHFPR6GwvPTQKRUutpXGLoLa_kkzz4AoSJBusYxpeDMTXykMqHhMwjqqEg7sgXHVWfEqvRQbi7KGMcVU8FGim0jteBLHXVauOV4LtJB1aNxKZnzGCkSQjQkwrwFn-vfKFNmoyTJs8nSxGE49XEWshbsFSOhzoUGnGElfCys7c-Xs48H53f25eP_Rz2Cjf5NNMDv4eU-bPqIoArb4ANYW8yW2SdEQAt5aAf6H7Qg_Bo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED9CBqEv69Z0rbeu00Ype3GwLUWyaV9Cs5BuSSjtMvJQMJZsQVnnhDQZrH99T_IHy7pB2ZNtWUKfp_v9pNMJ4IhqoVXia1dmnkSCwpmbaE7dLIyUDFHJKntryXjCh1P2edadNeCkOgtT-IeoF9yMZNj52gj4ItW_Cfntzc8O6mJzhvoZ46gmDSK6rH1HmaPHlm0xs_-PSrB0K2TMeOqkm8roEcLcBKxW4wy24boqa2Fo8r2zXsmOuv_DjeN_VuYFPC-RKOkVQ-clNLJ8B9q9HFn4j1_kmFjbULvovgOtcbkF34bTcW8w6pPF0oSs7ojaMGgl5YYPMSbrRNqzQsSszpNx72rU34Xp4NPXs6FbXsHgYh9R3808LhEFKCQ-Qmueak-by9O9MPFTfKa-EFGXsiRjVHGfR5HwgzQUKZWeDhSGvoJmPs-zfSBUJEjWOKYUnHlJgEQmMmwGIR0VaVc68LHqi1iV_snNNRm3ccVTsJFi20gOfKijLgqnHH-LdFB1aFzK5V2MBAkBGtJg7sD7-jdKlNkmSfJsvjZxGE58nEXMgb1iINS50JAzrESAhbXd-e_s49H5N_vy-ulR30Hroj_Az8mXN7AVIHwqDIMPoLlarrO3CH9W8tAO8we7LfrJ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MAFLD+predicts+cardiovascular+disease+risk+better+than+MASLD&rft.jtitle=Liver+international&rft.au=Pan%2C+Ziyan&rft.au=Shiha%2C+Gamal&rft.au=Esmat%2C+Gamal&rft.au=M%C3%A9ndez-S%C3%A1nchez%2C+Nahum&rft.date=2024-07-01&rft.eissn=1478-3231&rft_id=info:doi/10.1111%2Fliv.15931&rft_id=info%3Apmid%2F38641962&rft.externalDocID=38641962 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |